Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Feasibility of biomarker-driven strategy in high-risk LBCL: final results from Nordic Phase II study

Sirpa Leppa, MD, PhD, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, describes and outlines results from a Nordic Phase II trial which evaluated the feasibility and efficacy of a biological risk-adapted treatment strategy in young patients with high-risk aggressive B-cell lymphoma (NCT032931730). Biological high-risk was defined as the presence of at least one of the following factors: C-MYC translocation, BCL2 translocation, 17p/TP53 deletion, co-expression of MYC and BCL2, P53+ and/or CD5+. Patients who did not have high-risk biological factors were treated with four courses of biweekly R-CHOP with etoposide (R-CHOEP), and patients with high-risk factors were treated with four courses of dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (DA-EPOCH-R). Overall, the study found that DA-EPOCH-R did not provide a benefit when compared to R-CHOEP. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Beigene: Consultancy; Pfizer: Consultancy; Orion Pharma: Consultancy; Bayer: Research Funding; BMS: Consultancy, Research Funding; Gilead Sciences: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Research Funding; Genmab: Research Funding; Nordic Nanovector: Research Funding.